On May 2, Sannuo Biosensing Co., Ltd. announced that it has signed a final merger agreement with PTS Diagnostics, a privately held company. According to the agreement, Sanno will pay up to US$200 million in cash for the acquisition of PTS Diagnostics, including no More than $90 million in conditional business income targets to reach a payment plan.
It is understood that the US PTS diagnosis was established in 1992, headquartered in Indianapolis, Indiana, USA, and has a research and development organization in Sunnyvale, California. Is a leading global provider of innovative POCT diagnostic equipment supplier, is committed to providing professional POCT diagnostic equipment for patients and healthcare providers, to help them get the right information at the right time and make the right judgments.
The company's main product is CardioChek? Series of blood lipids, blood glucose analysis and monitoring equipment and A1CNow? The series of glycated hemoglobin (HbA1c) monitors, product marketing network covering 135 countries and regions around the world.
The PTS disclosed in the announcement diagnoses the financial situation in the past three years:
After the completion of the acquisition, Sannuo Bio will integrate the PTS diagnostic product line, the Trividia product line and the company's own products in the future to jointly create a product portfolio covering diabetes and a variety of chronic diseases. After the implementation of domestic graded treatment, the hospital, Diabetes and other chronic disease management at the primary health care institutions and individuals provides integrated products and services while providing integrated chronic disease management solutions.
Mr. Li Shaobo, Chairman and General Manager of Sannuo Bio said: “Sannuo Bio is committed to applying innovative biosensing technology to provide high quality products and services for patients with diabetes and other chronic diseases. Through continuous innovation, PTS diagnosis has become blood lipid and saccharification. Leading companies in the market for hemoglobin and other important real-time biometric products. Sanno Bio and PTS Diagnostics share a common vision and mission to improve the quality of life of our users. We admire and respect the achievements of PTS management teams and employees, and We are confident that we will continue to achieve our common goals. We will continue to grow our business, seek more global development opportunities, and provide more innovative and systematic solutions for the prevention and treatment of chronic diseases, allowing patients with diabetes and other chronic diseases. Live healthier."
Mr. Robert Huffstodt, Chairman and General Manager of PTS, said: "The core product portfolio of PTS Diagnostics (lipid and glycated hemoglobin detection system) will be well integrated with the blood glucose monitoring products that Sanno Bios focuses on. The combined companies can achieve no cooperation. The sharing of information will help improve the diagnosis and monitoring of many chronic diseases. In the future, both parties will jointly focus on providing fast, simple, portable and accurate medical equipment and information management systems for individuals and healthcare professionals. To change the business areas of preventive medicine, biometrics and test data connections."
Tuna Loin,Frozen Tuna Loin,Fresh Tuna Loin,Yellowfin Tuna Loin
ZHEJIANG RETRONX FOODSTUFF INDUSTRY CO.,LTD , https://www.retronxfoods.com